(Reuters) - Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/XWm0TmJLuMY/story01.htm
Read More
No comments:
Post a Comment